Complix N.V.

Complix N.V. is a biopharmaceutical company based in Belgium that is pioneering the use of biologics for challenging disease targets. The company was founded in 2008 and is dedicated to the discovery and development of protein therapeutics using its proprietary alphabody™ technology. Alphabodies, which are robust and versatile protein scaffolds unrelated to immunoglobulins, are inspired by naturally occurring motives. Complix has developed the proprietary Cell Penetrating Alphabody (CPAB) technology, allowing it to access a broad range of intracellular disease-related targets that are considered "intractable" by currently available drug formats, such as antibodies and small molecules. The company's most recent investment was a €1.20M grant investment received on 07 September 2020. This investment was made by Agentschap Innoveren & Ondernemen. Complix's focus on addressing challenging disease targets with its innovative biologic technology makes it an attractive prospect for potential venture capital investment. Its unique approach to developing protein therapeutics positions the company as a potentially disruptive force in the biotechnology and health care industries.